Pipeline Speed Bump Doesn't Shake AstraZeneca's $80 Billion Revenue Ambition

기사 요약

AstraZeneca (AZN) Q2 2026: EPS beats estimates at $2.63 despite missing revenue targets. Oncology sales up 16%. Get the full recap.